Non-Accredited Satellite Symposia

A Potential New Path to Pain Relief:  Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)

Presented by Cara Therapeutics, ASA Annual Meeting Supporter

Sunday, October 22 | 6:30 - 8 a.m. 
The Westin Boston Waterfront, Harbor Ballroom 1 and 2, Conference Level


Joseph Stauffer, D.O., M.B.A.

This symposium will describe how traditional mu opioid agonists play an important role in postoperative analgesia.  However, their use is associated with adverse effects such as respiratory depression, nausea and vomiting, which can delay postoperative recovery and increase healthcare costs.  In addition, mu opioid analgesics are responsible for morbidity and mortality due to the public health epidemics of abuse and overdose.  A novel peripherally acting kappa opioid receptor agonist (KORA), CR845, is currently in Phase 3 trials for postoperative pain (IV CR845) and Phase 2 trials for chronic pain (oral CR845).  Because of it's unique pharmacologic properties, CR845 has been shown to produce analgesia with little-to-no traditional mu opioid side effects and low abuse potential.  During this satellite symposium, the faculty will discuss analgesic drugs and techniques currently used in enhanced recovery after surgery (ERAS) protocols - an evolving paradigm for multimodal perioperative care, review the clinical data for CR845, and consider CR845's potential place in postoperative analgesia.  Register now.     

Clinical Considerations in Neuromuscular Blockade Management

Presented by Merck, ASA Industry Supporter

Sunday, October 22 | 12:00 - 1:00 p.m.
Boston Convention & Exhibition Center, Ballroom East, Ballroom Level


Peter Schoenwald, M.D.

This symposium will discuss clinical rationale and society guidelines related to neuromuscular monitoring.  It will also include clinical data for an FDA approved agent that reverses moderate and deep neuromuscular blockade.  No registration is necessary.

Disclaimer:  "Merck is pleased to sponsor this program to provide information consistent with FDA guidelines.  This program is not an accredited CME program and is not designed to meet any training and/or educational requirements.  This medical education program is for US health care professionals and health care business professionals only.  The speaker for this program is speaking on behalf of Merck."

Pharmacokinetics and Dynamics of Sublingual Sufentanil

Presented by AcelRx Pharmaceuticals, Inc.

Monday, October 23 | 6:30 - 8 a.m. 
The Westin Boston Waterfront, Grand Ballroom B-E


Eugene Viscusi, M.D.
Albert Dahan, M.D., Ph.D.
Dennis Fisher, M.D.

This symposium will discuss the pharmacokinetics and dynamics of sublingual sufentanil and a comparison to IV opioid administration.  You may register one of three ways:  online, at the door, or see an AcelRx Pharmaceuticals representative in Booth # 1435.   

Helpful Information

Early-bird savings end July 23!


Register  arrow


The countdown to Boston has begun.
Be there.

ASA Membership Matters

ASA members receive deep discounts on registration. Join today before you register!

Learn more about submission opportunities

Submission Info